Loading clinical trials...
Loading clinical trials...
Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vanderbilt University Medical Center
NCT07552727 · Metabolic Adaptation to High-Intensity Interval Training, Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
NCT06902246 · Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
NCT07175441 · Advanced Unresectable Hepatocellular Carcinoma
NCT07422753 · Hepatocellular Carcinoma (HCC)
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions